Pfizer Inc

PFE is in a Stage 4 decline within a long-term downtrend, exhibiting lower highs and lower lows with short EMAs beneath longer-term moving averages. Medium-term bias is bearish, while short-term timing is neutral after an oversold bounce extended price above the 9/21 EMAs. Execution posture is to trim into rallies approaching intermediate resistance around the 50 DMA and 200 DMA.

• ↑High earnings yield and 2.02% dividend yield, $9.8B returned to shareholders.
• ↑Q1 revenue of $14.5B up 7% ex-COVID; adjusted EPS $0.75 beat estimates.
• ↓Patent cliff ahead threatens revenue and margin sustainability.